Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Index by author

February 01, 1995; Volume 272,Issue 2
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Adachi, H

    1. You have access
      A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;
  2. Adrien, J

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  3. Aguilar, H

    1. You have access
      Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;
  4. Albrightson, C R

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  5. Alling, D W

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  6. Alvarez, I

    1. You have access
      Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;
  7. Andersson, R G

    1. You have access
      Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
      I G Johansson-Rydberg, N Grundström and R G Andersson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 786-790;
  8. Apparsundaram, S

    1. You have access
      Role of prejunctional beta adrenoceptors in rat cardiac sympathetic neurotransmission.
      S Apparsundaram and D C Eikenburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 519-526;
  9. Atchison, W D

    1. You have access
      The paralytic agent 2,4-dithiobiuret decreases open time of murine skeletal muscle acetylcholine receptor channels.
      J M Spitsbergen and W D Atchison
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 645-651;
  10. Awazu, S

    1. You have access
      Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells.
      M Tomita, M Hayashi and S Awazu
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 739-743;
  11. Azorlosa, J L

    1. You have access
      Marijuana smoking: effects of varying puff volume and breathhold duration.
      J L Azorlosa, M K Greenwald and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 560-569;

B

  1. Badger, A M

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  2. Banks, S M

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  3. Barg, J

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;
  4. Beauchamp, H T

    1. You have access
      In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;
  5. Bédard, P J

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  6. Bell, R L

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  7. Bemis, K G

    1. You have access
      In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;
  8. Berkhout, T A

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  9. Bigelow, G E

    1. You have access
      Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;
  10. Blanchet, P J

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  11. Bloom, F E

    1. You have access
      Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.
      J Raber, G F Koob and F E Bloom
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 815-824;
  12. Bonkovsky, H L

    1. You have access
      Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;
  13. Botla, R

    1. You have access
      Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;
  14. Boulanger, C M

    1. You have access
      Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;
  15. Bouska, J B

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  16. Bridal, T R

    1. You have access
      Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
      F G de Lorenzi, T R Bridal and W Spinelli
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 714-723;
  17. Bronk, S F

    1. You have access
      Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;
  18. Brooks, D W

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  19. Brune, K A

    1. You have access
      In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;
  20. Bugelski, P J

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  21. Butelman, E R

    1. You have access
      Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;
  22. Butler, A M

    1. You have access
      Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion.
      M Murray and A M Butler
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 639-644;

C

  1. Cable, E E

    1. You have access
      Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;
  2. Calon, F

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  3. Campos, H A

    1. You have access
      Interaction between noradrenergic and histamine-containing neurons in the rat vas deferens.
      H A Campos and J Domínguez
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 732-738;
  4. Carpéné, C

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;
  5. Carter, D B

    1. You have access
      [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;
  6. Carter, G W

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  7. Chang, R S

    1. You have access
      In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;
  8. Chastanet, M

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  9. Chiba, S

    1. You have access
      Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. You have access
      Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;
  10. Chikkala, D N

    1. You have access
      Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.
      J E Piletz, D N Chikkala and P Ernsberger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 581-587;
  11. Childers, S R

    1. You have access
      Behavioral and local cerebral metabolic effects of the novel tropane analog, 2 beta-propanoyl-3 beta-(4-tolyl)-tropane.
      L J Porrino, H M Davies and S R Childers
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 901-910;
  12. Collon, P

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;
  13. Colombo, M

    1. You have access
      Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;
  14. Cordi, A

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;
  15. Cuello, A C

    1. You have access
      Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain.
      L Garofalo and A C Cuello
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 527-545;

D

  1. Danner, R L

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  2. Dantzler, W H

    1. You have access
      Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules.
      W H Dantzler, K K Evans and S H Wright
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 663-672;
  3. Davies, H M

    1. You have access
      Behavioral and local cerebral metabolic effects of the novel tropane analog, 2 beta-propanoyl-3 beta-(4-tolyl)-tropane.
      L J Porrino, H M Davies and S R Childers
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 901-910;
  4. de Lorenzi, F G

    1. You have access
      Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
      F G de Lorenzi, T R Bridal and W Spinelli
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 714-723;
  5. Desforges, B

    1. You have access
      Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;
  6. Desta, B

    1. You have access
      Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;
  7. De Vry, J

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  8. Diana, M

    1. You have access
      Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;
  9. Dillon, G H

    1. You have access
      [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;
  10. Di Paolo, T

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  11. Domínguez, J

    1. You have access
      Interaction between noradrenergic and histamine-containing neurons in the rat vas deferens.
      H A Campos and J Domínguez
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 732-738;
  12. Donohue, S

    1. You have access
      Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;
  13. Drew, G M

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  14. Dubé, G P

    1. You have access
      In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;
  15. Dumont, Y

    1. You have access
      Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;
  16. Dykstra, L A

    1. You have access
      Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;

E

  1. Eikenburg, D C

    1. You have access
      Role of prejunctional beta adrenoceptors in rat cardiac sympathetic neurotransmission.
      S Apparsundaram and D C Eikenburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 519-526;
  2. Elin, R J

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  3. Ernsberger, P

    1. You have access
      Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.
      J E Piletz, D N Chikkala and P Ernsberger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 581-587;
  4. Evans, K K

    1. You have access
      Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules.
      W H Dantzler, K K Evans and S H Wright
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 663-672;

F

  1. Faiman, M D

    1. You have access
      Characterization of diethyldithiocarbamate methyl ester sulfine as an intermediate in the bioactivation of disulfiram.
      A Madan and M D Faiman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 775-780;
  2. Farfel, G M

    1. You have access
      Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 860-867;
    2. You have access
      Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 868-875;
  3. Farré, A J

    1. You have access
      Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;
  4. Fecho, K

    1. You have access
      Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;
  5. Finkel, M S

    1. You have access
      Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;
  6. Fournier, A

    1. You have access
      Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;
  7. Fox, M

    1. You have access
      Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
      N C Trippodo, B C Panchal and M Fox
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 619-627;
  8. Fride, E

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;
  9. Fujita, T

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  10. Fukui, H

    1. You have access
      Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;
  11. Funae, Y

    1. You have access
      Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;
  12. Furukawa, Y

    1. You have access
      Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. You have access
      Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;

G

  1. Garaulet, J V

    1. You have access
      Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
      J V Garaulet, M V Milanés and M L Laorden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 658-662;
  2. Garofalo, L

    1. You have access
      Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain.
      L Garofalo and A C Cuello
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 527-545;
  3. Gessa, G

    1. You have access
      Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;
  4. Gibson, R E

    1. You have access
      In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;
  5. Glaser, T

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  6. Glavin, G B

    1. You have access
      Some novel 5-hydroxytryptamine1A (5-HT1A) receptor agonists reduce gastric acid and pepsin secretion, reduce experimental gastric mucosal injury and enhance gastric mucus in rats.
      A J Farré, M Colombo, I Alvarez and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 832-837;
  7. Goldberg, S R

    1. You have access
      Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;
  8. Gores, G J

    1. You have access
      Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;
  9. Grattagliano, I

    1. You have access
      Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;
  10. Greenwald, M K

    1. You have access
      Marijuana smoking: effects of varying puff volume and breathhold duration.
      J L Azorlosa, M K Greenwald and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 560-569;
  11. Griffiths, R R

    1. You have access
      Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
      G K Mumford, C R Rush and R R Griffiths
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 570-580;
  12. Grundström, N

    1. You have access
      Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
      I G Johansson-Rydberg, N Grundström and R G Andersson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 786-790;
  13. Guenthner, T M

    1. You have access
      Metabolism of allylbenzene 2',3'-oxide and estragole 2',3'-oxide in the isolated perfused rat liver.
      G Luo and T M Guenthner
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 588-596;

H

  1. Hamilton, B J

    1. You have access
      [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;
  2. Hamon, M

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  3. Harris, R R

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  4. Hattler, B G

    1. You have access
      Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;
  5. Hayashi, M

    1. You have access
      Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells.
      M Tomita, M Hayashi and S Awazu
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 739-743;
  6. Heldman, E

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;
  7. Hilditch, A

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  8. Hiroi, T

    1. You have access
      Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;
  9. Ho, A

    1. You have access
      Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study.
      I M Maisonneuve, A Ho and M J Kreek
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 652-657;
  10. Hosseini, J M

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  11. Hoyano, Y

    1. You have access
      Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
  12. Hudson, A

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;
  13. Hunt, A A

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

I

  1. Iga, T

    1. You have access
      Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;
  2. Ihara, Y

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  3. Im, W B

    1. You have access
      [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;
  4. Imaoka, S

    1. You have access
      Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;
  5. Inoue, T

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;

J

  1. Jackson, B

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  2. Jakubowski, J A

    1. You have access
      In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;
  3. Johansson-Rydberg, I G

    1. You have access
      Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
      I G Johansson-Rydberg, N Grundström and R G Andersson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 786-790;
  4. Jolas, T

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  5. Judd, D B

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;

K

  1. Kagitani, Y

    1. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;
  2. Kasama, M

    1. You have access
      Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. You have access
      Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;
  3. Kawamura, T

    1. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;
  4. Kawase, Y

    1. You have access
      Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
  5. Kerns, W D

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  6. Kirchengast, M

    1. You have access
      Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;
  7. Koev, C A

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  8. Koob, G F

    1. You have access
      Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.
      J Raber, G F Koob and F E Bloom
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 815-824;
  9. Kotaki, H

    1. You have access
      Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;
  10. Kreek, M J

    1. You have access
      Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study.
      I M Maisonneuve, A Ho and M J Kreek
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 652-657;
  11. Kurtz, W L

    1. You have access
      In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
      G P Dubé, J A Jakubowski, K A Brune, K G Bemis and W L Kurtz
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 799-807;

L

  1. Lafontan, M

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;
  2. Lambrecht, R W

    1. You have access
      Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;
  3. Lanni, C

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  4. Laorden, M L

    1. You have access
      Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
      J V Garaulet, M V Milanés and M L Laorden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 658-662;
  5. Laporte, A M

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  6. Lauterburg, B H

    1. You have access
      Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;
  7. Levine, D M

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  8. Levy, R

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;
  9. Liebson, I A

    1. You have access
      Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;
  10. Linden, J

    1. You have access
      Comparison of A4 and A2a binding sites in striatum and COS cells transfected with adenosine A2a receptors.
      D R Luthin and J Linden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 511-518;
  11. Little, H J

    1. You have access
      Identification of distinct components, with different time courses, of the changes in response to convulsive stimuli during ethanol withdrawal.
      W P Watson and H J Little
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 876-884;
  12. Luo, G

    1. You have access
      Metabolism of allylbenzene 2',3'-oxide and estragole 2',3'-oxide in the isolated perfused rat liver.
      G Luo and T M Guenthner
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 588-596;
  13. Luthin, D R

    1. You have access
      Comparison of A4 and A2a binding sites in striatum and COS cells transfected with adenosine A2a receptors.
      D R Luthin and J Linden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 511-518;
  14. Lysle, D T

    1. You have access
      Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;

M

  1. Madan, A

    1. You have access
      Characterization of diethyldithiocarbamate methyl ester sulfine as an intermediate in the bioactivation of disulfiram.
      A Madan and M D Faiman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 775-780;
  2. Maisonneuve, I M

    1. You have access
      Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study.
      I M Maisonneuve, A Ho and M J Kreek
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 652-657;
  3. Malo, P E

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  4. Martel, J C

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  5. Maslonek, K A

    1. You have access
      Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation.
      K Fecho, K A Maslonek, L A Dykstra and D T Lysle
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 477-483;
  6. Mayer, O H

    1. You have access
      Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;
  7. Mechoulam, R

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;
  8. Middlemiss, D

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  9. Milanés, M V

    1. You have access
      Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
      J V Garaulet, M V Milanés and M L Laorden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 658-662;
  10. Min, K R

    1. You have access
      Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
  11. Moerschbaecher, J M

    1. You have access
      Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
      E D Pakarinen, J H Woods and J M Moerschbaecher
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 552-559;
  12. Mue, S

    1. You have access
      Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
  13. Mullikin-Kilpatrick, D

    1. You have access
      Inhibition of dihydropyridine-sensitive Ca++ channels by ethanol in undifferentiated and nerve growth factor-treated PC12 cells: interaction with the inactivated state.
      D Mullikin-Kilpatrick and S N Treistman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 489-497;
  14. Mumford, G K

    1. You have access
      Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
      G K Mumford, C R Rush and R R Griffiths
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 570-580;
  15. Muntoni, A

    1. You have access
      Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;
  16. Murray, M

    1. You have access
      Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion.
      M Murray and A M Butler
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 639-644;

N

  1. Nagai, H

    1. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;
  2. Nakano, H

    1. You have access
      Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
  3. Nakashima, M

    1. You have access
      Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;
  4. Narita, Y

    1. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;
  5. Natanson, C

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  6. Nieves, A L

    1. You have access
      Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;
  7. Nocerini, M R

    1. You have access
      A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;
  8. Nutt, D

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;

O

  1. Oddis, C V

    1. You have access
      Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;
  2. Oguchi, T

    1. You have access
      Selective inhibition by zatebradine and discrete parasympathetic stimulation of the positive chronotropic response to sympathetic stimulation in anesthetized dogs.
      Y Furukawa, H Nakano, T Oguchi, M Kasama, Y Hoyano and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 744-749;
    2. You have access
      Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;
  3. Ohishi, N

    1. You have access
      Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;
  4. Ohnishi, A

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  5. Ohtani, M

    1. You have access
      Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;
  6. Ohuchi, K

    1. You have access
      Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
  7. Organ, A J

    1. You have access
      Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
      C R Albrightson, P J Bugelski, T A Berkhout, B Jackson, W D Kerns, A J Organ and A M Badger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 689-698;
  8. Orita, Y

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  9. Orzi, F

    1. You have access
      Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;
  10. Otis, E R

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;

P

  1. Pakarinen, E D

    1. You have access
      Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
      E D Pakarinen, J H Woods and J M Moerschbaecher
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 552-559;
  2. Panchal, B C

    1. You have access
      Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
      N C Trippodo, B C Panchal and M Fox
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 619-627;
  3. Parker, T S

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  4. Pepe, J A

    1. You have access
      Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;
  5. Perrault, G

    1. You have access
      Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.
      D J Sanger and G Perrault
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 708-713;
  6. Pettigrew, K

    1. You have access
      Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;
  7. Piercey, M F

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  8. Piletz, J E

    1. You have access
      Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.
      J E Piletz, D N Chikkala and P Ernsberger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 581-587;
  9. Pistis, M

    1. You have access
      Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.
      M Diana, M Pistis, A Muntoni and G Gessa
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 781-785;
  10. Polley, J

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  11. Porrino, L J

    1. You have access
      Behavioral and local cerebral metabolic effects of the novel tropane analog, 2 beta-propanoyl-3 beta-(4-tolyl)-tropane.
      L J Porrino, H M Davies and S R Childers
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 901-910;
  12. Potchoiba, M J

    1. You have access
      A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;
  13. Prada, J

    1. You have access
      Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;
  14. Pregenzer, J F

    1. You have access
      [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
      G H Dillon, W B Im, J F Pregenzer, D B Carter and B J Hamilton
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 597-603;
  15. Preston, K L

    1. You have access
      Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;

Q

  1. Quezado, Z M

    1. You have access
      Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock.
      Z M Quezado, C Natanson, S M Banks, D W Alling, C A Koev, R L Danner, R J Elin, J M Hosseini, T S Parker and D M Levine
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 604-611;
  2. Quirion, R

    1. You have access
      Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;

R

  1. Raber, J

    1. You have access
      Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response.
      J Raber, G F Koob and F E Bloom
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 815-824;
  2. Remaury, A

    1. You have access
      Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
      C Carpéné, P Collon, A Remaury, A Cordi, A Hudson, D Nutt and M Lafontan
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 681-688;
  3. Robertson, M J

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  4. Ross, B C

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  5. Rouveix, B

    1. You have access
      Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;
  6. Rush, C R

    1. You have access
      Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
      G K Mumford, C R Rush and R R Griffiths
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 570-580;
  7. Russo, S M

    1. You have access
      Tissue distribution of zinc-mesoporphyrin in rats: relationship to inhibition of heme oxygenase.
      S M Russo, J A Pepe, S Donohue, E E Cable, R W Lambrecht and H L Bonkovsky
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 766-774;

S

  1. Saeki, T

    1. You have access
      A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;
  2. Saito, I

    1. You have access
      A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;
  3. Sanger, D J

    1. You have access
      Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.
      D J Sanger and G Perrault
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 708-713;
  4. Sawada, Y

    1. You have access
      Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
      M Ohtani, H Kotaki, Y Sawada and T Iga
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 505-510;
  5. Sawaki, S

    1. You have access
      Are negative chronotropic and inotropic responses to adenosine differentiated at the receptor or postreceptor levels in isolated dog hearts?
      T Oguchi, Y Furukawa, S Sawaki, M Kasama and S Chiba
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 838-844;
  6. Saya, D

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;
  7. Schindler, C W

    1. You have access
      Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;
  8. Schranz, C

    1. You have access
      Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;
  9. Schreiber, R

    1. You have access
      Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
      T Jolas, R Schreiber, A M Laporte, M Chastanet, J De Vry, T Glaser, J Adrien and M Hamon
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 920-929;
  10. Seiden, L S

    1. You have access
      Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 860-867;
    2. You have access
      Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan.
      G M Farfel and L S Seiden
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 868-875;
  11. Shinyama, H

    1. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;
  12. Siegl, P K

    1. You have access
      In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
      H T Beauchamp, R S Chang, P K Siegl and R E Gibson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 612-618;
  13. Silber, B M

    1. You have access
      A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;
  14. Simmons, R L

    1. You have access
      Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship.
      M S Finkel, C V Oddis, O H Mayer, B G Hattler and R L Simmons
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 945-952;
  15. Sinet, M

    1. You have access
      Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;
  16. Smith, C B

    1. You have access
      Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;
  17. Sokoloff, L

    1. You have access
      Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;
  18. Souda, S

    1. You have access
      A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;
  19. Spada, C S

    1. You have access
      Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;
  20. Spinelli, W

    1. You have access
      Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
      F G de Lorenzi, T R Bridal and W Spinelli
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 714-723;
  21. Spitsbergen, J M

    1. You have access
      The paralytic agent 2,4-dithiobiuret decreases open time of murine skeletal muscle acetylcholine receptor channels.
      J M Spitsbergen and W D Atchison
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 645-651;
  22. Spivey, J R

    1. You have access
      Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
      R Botla, J R Spivey, H Aguilar, S F Bronk and G J Gores
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 930-938;
  23. St-Pierre, S

    1. You have access
      Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
      Y Dumont, A Fournier, S St-Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 673-680;
  24. Stewart, A O

    1. You have access
      Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
      R L Bell, J B Bouska, P E Malo, C Lanni, R R Harris, E R Otis, A O Stewart, D W Brooks and G W Carter
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 724-731;
  25. Stitzer, M L

    1. You have access
      Marijuana smoking: effects of varying puff volume and breathhold duration.
      J L Azorlosa, M K Greenwald and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 560-569;
  26. Strain, E C

    1. You have access
      Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 628-638;
  27. Sun, Y

    1. You have access
      Effects of acute and delayed effects of prior chronic cocaine administration on regional rates of cerebral protein synthesis in rats.
      F Orzi, Y Sun, K Pettigrew, L Sokoloff and C B Smith
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 892-900;

T

  1. Takagi, N

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  2. Takase, Y

    1. You have access
      A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;
  3. Tanabe, J

    1. You have access
      Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
  4. Tanaka, T

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  5. Tella, S R

    1. You have access
      Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
      C W Schindler, S R Tella, J Prada and S R Goldberg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 791-798;
  6. Tensfeldt, T G

    1. You have access
      A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.
      M J Potchoiba, T G Tensfeldt, M R Nocerini and B M Silber
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 953-962;
  7. Tomita, M

    1. You have access
      Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells.
      M Tomita, M Hayashi and S Awazu
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 739-743;
  8. Toyoki, T

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  9. Travers, A

    1. You have access
      Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
      A Hilditch, A A Hunt, A Travers, J Polley, G M Drew, D Middlemiss, D B Judd, B C Ross and M J Robertson
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 750-757;
  10. Treistman, S N

    1. You have access
      Inhibition of dihydropyridine-sensitive Ca++ channels by ethanol in undifferentiated and nerve growth factor-treated PC12 cells: interaction with the inactivated state.
      D Mullikin-Kilpatrick and S N Treistman
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 489-497;
  11. Trippodo, N C

    1. You have access
      Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
      N C Trippodo, B C Panchal and M Fox
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 619-627;
  12. Tuckett, R P

    1. You have access
      Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;

U

  1. Uchida, T

    1. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;

V

  1. Vanhoutte, P M

    1. You have access
      Previous exposure to bradykinin unmasks an endothelium-dependent relaxation to the converting enzyme inhibitor trandolaprilat in isolated canine coronary arteries.
      B Desta, M Nakashima, M Kirchengast, P M Vanhoutte and C M Boulanger
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 885-891;
  2. Veyries, M L

    1. You have access
      Effects of morphine on the pathogenesis of murine Friend retrovirus infection.
      M L Veyries, M Sinet, B Desforges and B Rouveix
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 498-504;
  3. Vogel, Z

    1. You have access
      Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
      E Fride, J Barg, R Levy, D Saya, E Heldman, R Mechoulam and Z Vogel
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 699-707;

W

  1. Walters, R R

    1. You have access
      Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
      P J Blanchet, F Calon, J C Martel, P J Bédard, T Di Paolo, R R Walters and M F Piercey
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 854-859;
  2. Watanabe, M

    1. You have access
      Suppression of interleukin-1 alpha production by protein kinase C activators in human vascular endothelial cells.
      M Watanabe, Y Kawase, J Tanabe, K R Min, S Mue and K Ohuchi
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 808-814;
    2. You have access
      Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats.
      H Shinyama, H Nagai, T Kawamura, Y Narita, T Uchida, M Watanabe and Y Kagitani
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 911-919;
  3. Watson, W P

    1. You have access
      Identification of distinct components, with different time courses, of the changes in response to convulsive stimuli during ethanol withdrawal.
      W P Watson and H J Little
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 876-884;
  4. Wieland, P

    1. You have access
      Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione.
      I Grattagliano, P Wieland, C Schranz and B H Lauterburg
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 484-488;
  5. Williams, L S

    1. You have access
      Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;
  6. Winger, G

    1. You have access
      Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;
  7. Woods, J H

    1. You have access
      Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
      E D Pakarinen, J H Woods and J M Moerschbaecher
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 552-559;
    2. You have access
      Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;
  8. Woodward, D F

    1. You have access
      Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen.
      D F Woodward, A L Nieves, C S Spada, L S Williams and R P Tuckett
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 758-765;
  9. Wright, S H

    1. You have access
      Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules.
      W H Dantzler, K K Evans and S H Wright
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 663-672;

Y

  1. Yabusaki, Y

    1. You have access
      Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
      T Hiroi, N Ohishi, S Imaoka, Y Yabusaki, H Fukui and Y Funae
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 939-944;
  2. Yamamura, Y

    1. You have access
      Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
      A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 546-551;
  3. Yoshitake, S

    1. You have access
      A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
      T Saeki, H Adachi, Y Takase, S Yoshitake, S Souda and I Saito
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 825-831;

Z

  1. Zernig, G

    1. You have access
      Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
      E R Butelman, G Winger, G Zernig and J H Woods
      Journal of Pharmacology and Experimental Therapeutics February 1995, 272 (2) 845-853;
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 272, Issue 2
1 Feb 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
  • Functional Selectivity and Classical Concepts of Quantitative Pharmacology
  • Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
  • The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data
  • A METHOD FOR DETERMINING LOSS OF PAIN SENSATION
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics